18F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer
- 7 February 2020
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
Abstract
The study objective was to investigate the role of 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography combined with computed tomography (PET-CT) as an indirect determination of the differentiation status of metastases and for the prediction of radioactive iodine (RAI) therapy response in patients with metastatic differentiated thyroid cancer.Materials and methods. The 40 metastatic differentiated thyroid cancer patients were enrolled in the study that underwent both post-therapeutic radioiodine scan and PET-CT at the same period.Results. The study found that 12 (30 %) patients responded to RAI therapy. The remaining 28 (70 %) patients not responded to RAI therapy showed stabilization or progression. The accumulation of radioiodine by metastases positively correlated with the total response rate, while the 18 F-FDG avidity is negative. Significant direct correlation with response rate was observed in the group with only radioiodine uptake. However, this correlation was not observed in the patients with both tracers uptake. The patients with 18 F-FDG-positive metastases showed poor response to RAI therapy, regardless of the degree of radioiodine uptake.Conclusion. The 18 F-FDG uptake by metastases is a predictor of a poor response to RAI therapy, even in the presence of RAI uptake. The use of 18 F-FDG PET-CT in patients with metastatic differentiated thyroid cancer can be recommended at the beginning of RAI therapy to clarify the prognosis and provide a personalized approach to the treatment and observation of the most difficult category of patients.Keywords
This publication has 20 references indexed in Scilit:
- Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancerBest Practice & Research Clinical Endocrinology & Metabolism, 2017
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablationNuclear Medicine Communications, 2014
- Definition and management of radioactive iodine-refractory differentiated thyroid cancerThe Lancet Diabetes & Endocrinology, 2014
- Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in OncologyEndocrinology and Metabolism, 2014
- Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directionsExpert Review of Endocrinology & Metabolism, 2012
- Standard and Emerging Therapies for Metastatic Differentiated Thyroid CancerThe Oncologist, 2010
- Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosisCancer, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006
- Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid CancerThe New England Journal of Medicine, 1983